Educational use only
Cardiovascular symptoms, vascular disease, erectile dysfunction, clotting disorders, and blood-pressure concerns need licensed medical care. This page is not a treatment or prevention guide.
Identity snapshot
| Common names | Vesugen, Vezugen, KED peptide |
|---|---|
| Sequence | KED - Lys-Glu-Asp |
| Type | Synthetic tripeptide |
| Stated target in Khavinson table | Vascular function |
| Natural-complex neighbor | Ventfort is commonly presented as the Cytomax blood-vessel peptide complex. |
Why KED causes search confusion
KED is the full sequence for Vesugen, but KED also appears inside several longer Khavinson sequences: Prostamax KEDP, Livagen KEDA, Pancragen KEDW, and Testagen KEDG. A search result mentioning "KED" is therefore not always about Vesugen unless the vascular context or full name is present.
Evidence map
Vesugen/KED literature is usually mechanism-heavy and frequently Russian-language. Search clusters include vasoprotection, endothelial function, atherosclerosis/restenosis mechanisms, and vascular aging. These are research contexts, not proof that an online KED product treats vascular disease.
Better wording: "KED is researched in vascular-function models" is safer and more precise than "Vesugen improves circulation."
Vesugen vascular benefits from studies, dosage from studies, and side effects
Searchers often ask whether Vesugen improves blood flow, endothelial function, erectile dysfunction, blood pressure, or vascular aging, plus Vesugen dosage and side effects. This page uses those search terms because they are real search flow, but answers them through study-only dose/exposure context and reported academic endpoints.
| Source context | Study-only dose or exposure | Reported benefit endpoint | Interpretation limit |
|---|---|---|---|
| 2015 Advances in Gerontology vascular-culture paper | Rat organotypic vascular cultures used vesugen at 0.05 ng/mL; dissociated rat aorta endothelial cultures used 20 ng/mL. | Ki-67 proliferation-marker expression and vascular-cell culture growth endpoints. | Rat in-vitro concentrations; not human Vesugen dosage or blood-flow guidance. |
| 2016 PubMed-indexed KED atherosclerosis/restenosis abstract | In-vitro endothelial context; the accessible abstract does not state a human dose. | Endothelin-1, connexin-mediated cell interaction, and sirtuin-1 expression markers. | Mechanism-oriented vascular biology markers, not proof of cardiovascular treatment benefit. |
| 2013 PubMed-indexed Vezugen lower-limb insufficiency abstract | The accessible abstract reports a course of Vezugen monotherapy in 41 post-surgery patients but does not state a dose. | Reported clinical and ultrasound blood-flow parameter improvements in lower limbs. | Russian-language abstract with limited accessible methods; not a dosing guideline or proof for vascular disease treatment. |
| 2014 Khavinson short-peptide table | No consumer dose; identifies Vezugen/Vesugen as KED - Lys-Glu-Asp. | Vascular-function activity category. | Identity and target mapping, not legal or medical-use guidance. |
Vesugen side effects: known vs unknown
Side effects and contraindications cannot be inferred from the KED sequence alone. The reviewed sources do not establish reliable adverse-event rates, route-specific risks, drug-interaction risks, or contraindications for consumer Vesugen products. Cardiovascular contexts are high stakes, and online peptide claims should not be used to change prescription drugs, anticoagulants, blood-pressure treatment, or clinician-directed care.
FDA status and legal status
Vesugen FDA status and Vesugen legal status searches should be answered by product and jurisdiction. This page does not identify an FDA-approved Vesugen/KED drug in the United States as of the May 5, 2026 review. FDA-approved status can be checked through Drugs@FDA and the Orange Book; compounded products are not FDA-approved, and research-labeled products are not automatically FDA-approved, safe, effective, or legally marketed for human use.
Sources
- Khavinson, "Peptides, Genome, Aging" (2014) - KED/Vezugen table entry.
- PubMed: KED molecular aspects in atherosclerosis and restenosis.
- PubMed: Vezugen and lower-limb chronic arterial insufficiency abstract - limited Russian-language blood-flow study context.
- Khavinson et al., vascular endothelial cell culture paper - vesugen/Ki-67 study exposure context.
- PubMed: KED molecular-genetic review entry - illustrates KED sequence reuse in literature.
- FDA: how to check whether a drug is approved - legal-status verification context.
- FDA compounding Q&A - U.S. safety and approval context.